These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 27103428)

  • 1. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study.
    Guevara M; Barricarte A; Torroba L; Herranz M; Gil-Setas A; Gil F; Bernaola E; Ezpeleta C; Castilla J;
    Euro Surveill; 2016; 21(14):. PubMed ID: 27103428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
    Harboe ZB; Dalby T; Weinberger DM; Benfield T; Mølbak K; Slotved HC; Suppli CH; Konradsen HB; Valentiner-Branth P
    Clin Infect Dis; 2014 Oct; 59(8):1066-73. PubMed ID: 25034421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
    PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage.
    Ciruela P; Izquierdo C; Broner S; Muñoz-Almagro C; Hernández S; Ardanuy C; Pallarés R; Domínguez A; Jané M;
    Vaccine; 2018 Nov; 36(50):7744-7752. PubMed ID: 30473132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
    Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M
    Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.
    Ingels H; Rasmussen J; Andersen PH; Harboe ZB; Glismann S; Konradsen H; Hoffmann S; Valentiner-Branth P; Lambertsen L;
    Vaccine; 2012 Jun; 30(26):3944-50. PubMed ID: 22504662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
    Camilli R; D'Ambrosio F; Del Grosso M; Pimentel de Araujo F; Caporali MG; Del Manso M; Gherardi G; D'Ancona F; Pantosti A;
    Vaccine; 2017 Aug; 35(35 Pt B):4587-4593. PubMed ID: 28716556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.
    Demczuk WH; Martin I; Griffith A; Lefebvre B; McGeer A; Lovgren M; Tyrrell GJ; Desai S; Sherrard L; Adam H; Gilmour M; Zhanel GG; ;
    Can J Microbiol; 2013 Dec; 59(12):778-88. PubMed ID: 24313450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.
    Shigayeva A; Rudnick W; Green K; Chen DK; Demczuk W; Gold WL; Johnstone J; Kitai I; Krajden S; Lovinsky R; Muller M; Powis J; Rau N; Walmsley S; Tyrrell G; Bitnun A; McGeer A;
    Clin Infect Dis; 2016 Jan; 62(2):139-47. PubMed ID: 26354970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].
    Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany.
    Perniciaro S; Imöhl M; Fitzner C; van der Linden M
    PLoS One; 2019; 14(1):e0210278. PubMed ID: 30625215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
    van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
    Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
    Domínguez Á; Ciruela P; Hernández S; García-García JJ; Soldevila N; Izquierdo C; Moraga-Llop F; Díaz A; F de Sevilla M; González-Peris S; Campins M; Uriona S; Martínez-Osorio J; Solé-Ribalta A; Codina G; Esteva C; Planes AM; Muñoz-Almagro C; Salleras L
    PLoS One; 2017; 12(8):e0183191. PubMed ID: 28806737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.
    Barricarte A; Castilla J; Gil-Setas A; Torroba L; Navarro-Alonso JA; Irisarri F; Arriazu M
    Clin Infect Dis; 2007 Jun; 44(11):1436-41. PubMed ID: 17479939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.